BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $203,000 | -58.1% | 3,228 | -59.6% | 0.53% | -21.2% |
| Q2 2017 | $484,000 | -33.9% | 7,998 | -39.2% | 0.67% | +3.2% |
| Q1 2017 | $732,000 | -30.7% | 13,152 | -44.8% | 0.65% | +6.1% |
| Q4 2016 | $1,056,000 | -40.7% | 23,825 | -36.3% | 0.61% | -41.7% |
| Q3 2016 | $1,782,000 | +2.4% | 37,431 | -2.8% | 1.05% | -0.1% |
| Q2 2016 | $1,741,000 | +5.8% | 38,496 | -3.9% | 1.05% | +9.6% |
| Q1 2016 | $1,646,000 | +8.9% | 40,075 | +1.1% | 0.96% | +8.0% |
| Q4 2015 | $1,512,000 | +19.1% | 39,644 | +2.6% | 0.89% | +14.0% |
| Q3 2015 | $1,270,000 | -54.3% | 38,657 | -2.6% | 0.78% | -49.6% |
| Q2 2015 | $2,776,000 | -42.1% | 39,690 | -43.3% | 1.54% | -34.2% |
| Q1 2015 | $4,792,000 | -27.0% | 69,954 | -21.8% | 2.34% | -8.2% |
| Q4 2014 | $6,560,000 | -28.4% | 89,509 | -29.9% | 2.55% | -4.0% |
| Q3 2014 | $9,168,000 | -21.5% | 127,747 | -21.0% | 2.66% | -3.0% |
| Q2 2014 | $11,684,000 | -3.1% | 161,604 | -1.4% | 2.74% | -3.4% |
| Q1 2014 | $12,056,000 | +2.9% | 163,854 | -2.8% | 2.84% | +7.1% |
| Q4 2013 | $11,721,000 | -23.2% | 168,522 | -27.4% | 2.65% | -3.9% |
| Q3 2013 | $15,252,000 | -11.9% | 232,176 | -7.1% | 2.76% | -11.6% |
| Q2 2013 | $17,304,000 | – | 249,809 | – | 3.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |